Immune-mediated insights into clinical and specific autoantibodies in acute and chronic immune-mediated nodo-paranodopathies

Abstract

The recognition of the molecular structures, namely the node of Ranvier and the axonal regions surrounding it (the paranode and juxtaparanode), as the primary target for specific autoantibodies has introduced a new site for neurological location (microtopographic structures), in contrast to the prevailing understanding, in which lesions to neural macrostructures (roots, nerves, and/or plexus) were the focus of semiologists and electrophysiologists for topographic, syndromic, and nosological diagnoses. Therefore, there was a need to understand and characterize the components of these neural microstructures that are grouped in small regions within the nerve to optimize clinical and therapeutic reasoning.

Keywords

Neuropathies - Neuritis

Authors' Contributions

All authors contributed to the conceptualization and design of the work, data acquisition, analysis and/or interpretation of data, and writing or review of the manuscript. All authors approved the final version of the manuscript and agree to be responsible for all aspects of the work.

Editor-in-Chief: Hélio A. G. Teive.

Associate Editor: Francisco Gondim.

Publikationsverlauf

Eingereicht: 22. Oktober 2024

Angenommen: 26. Dezember 2024

Artikel online veröffentlicht:
19. März 2025

• References

• 1 Van den Bergh PYK, van Doorn PA. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst 2021; 26 (03) 242-268
• 2 Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 2019; 18 (08) 784-794
• 3 Koike H, Kadoya M, Kaida KI. et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 2017; 88 (06) 465-473
• 4 Schafer DP, Bansal R, Hedstrom KL, Pfeiffer SE, Rasband MN. Does paranode formation and maintenance require partitioning of neurofascin 155 into lipid rafts?. J Neurosci 2004; 24 (13) 3176-3185
• 5 Uncini A, Vallat JM. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground. J Neurol Neurosurg Psychiatry 2018; 89 (06) 627-635
• 6 Rinaldi S, Bennett DL. Pathogenic mechanisms in inflammatory and paraproteinaemic peripheral neuropathies. Curr Opin Neurol 2014; 27 (05) 541-551
• 7 Svahn J, Antoine JC, Camdessanché JP. Pathophysiology and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathies. Rev Neurol (Paris) 2014; 170 (12) 808-817
• 8 Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain 2009; 132 (Pt 1): 260-273
• 9 Uncini A. Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment. J Peripher Nerv Syst 2023; 28 (Suppl. 03) S23-S35
• 10 Becker EB, Zuliani L, Pettingill R. et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 2012; 83 (04) 437-440
• 11 Uncini A. A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 2012; 235 (02) 513-516
• 12 Kira JI, Yamasaki R, Ogata H. Anti-neurofascin autoantibody and demyelination. Neurochem Int 2019; 130: 104360
• 13 Fujita A, Ogata H, Yamasaki R, Matsushita T, Kira JI. Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2018; 384: 107-112
• 14 Ogata H, Matsuse D, Yamasaki R. et al. A nationwide survey of combined central and peripheral demyelination in Japan. J Neurol Neurosurg Psychiatry 2016; 87 (01) 29-36
• 15 Manso C, Querol L, Mekaouche M, Illa I, Devaux JJ. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 2016; 139 (Pt 6): 1700-1712
• 16 Kriebel M, Wuchter J, Trinks S, Volkmer H. Neurofascin: a switch between neuronal plasticity and stability. Int J Biochem Cell Biol 2012; 44 (05) 694-697
• 17 Hortsch M, Nagaraj K, Mualla R. The L1 family of cell adhesion molecules: a sickening number of mutations and protein functions. Adv Neurobiol 2014; 8: 195-229
• 18 Ogata H, Yamasaki R, Hiwatashi A. et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015; 2 (10) 960-971
• 19 Devaux JJ, Miura Y, Fukami Y. et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86 (09) 800-807
• 20 Martinez-Martinez L, Lleixà MC, Boera-Carnicero G. et al. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. J Neuroinflammation 2017; 14 (01) 224
• 21 Bailly L, Mongin M, Delorme C. et al. Tremor Associated with Chronic Inflammatory Demyelinating Polyneuropathy and Anti-Neurofascin-155 Antibodies. Tremor Other Hyperkinet Mov (N Y) 2018; 8: 606
• 22 Garg N, Park SB, Yiannikas C. et al. Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. Muscle Nerve 2018; 57 (05) 848-851
• 23 Shimizu M, Koda T, Nakatsuji Y, Ogata H, Kira JI, Mochizuki H. [A case of anti-neurofascin 155 antibody-positive combined central and peripheral demyelination successfully treated with plasma exchange]. Rinsho Shinkeigaku 2017; 57 (01) 41-44
• 24 Tajima Y, Matsumura M, Yaguchi H, Mito Y. Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. Intern Med 2018; 57 (06) 867-871
• 25 Stich O, Perera S, Berger B. et al. Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis. J Neurol Sci 2016; 364: 29-32
• 26 Querol L, Siles AM, Alba-Rovira R. et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep 2017; 7 (01) 14411 . ISSN 2045-2322.
• 27 Kawamura N, Yamasaki R, Yonekawa T. et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology 2013; 81 (08) 714-722
• 28 Miura Y, Devaux JJ, Fukami Y. et al; CNTN1-CIDP Study Group. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015; 138 (Pt 6): 1484-1491
• 29 Kuwabara S, Misawa S, Mori M. Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. J Neurol Neurosurg Psychiatry 2017; 88 (06) 459
• 30 Illa I. ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. J Peripher Nerv Syst 2017; 22 (04) 418-424
• 31 Doppler K, Appeltshauser L, Villmann C. et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 2016; 139 (Pt 10): 2617-2630
• 32 Querol L, Illa I. Paranodal and other autoantibodies in chronic inflammatory neuropathies. Curr Opin Neurol 2015; 28 (05) 474-479
• 33 Briani C, Salvalaggio A, Ruiz M. et al. Tongue tremor in neurofascin-155 IgG4 seropositive chronic inflammatory polyradiculoneuropathy. J Neuroimmunol 2019; 330: 178-180
• 34 Pascual-Goñi E, Martín-Aguilar L, Querol L. Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy. Curr Opin Neurol 2019; 32 (05) 651-657
• 35 Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology 2019; 52 (3-4): 161-172
• 36 Ikeda S, Koike H, Nishi R. et al. Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2019; 90 (09) 988-996
• 37 Aktas O. Shifting borders, crossing boundaries: The case of combined central and peripheral demyelination. Mult Scler 2018; 24 (04) 550-551